SCHEMBL6477640

SCHEMBL6477640

C=C(/C=C/C(=O)O)c1cccc(-c2cc3c(cc2C)C(C)(C)CCC3(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 14/20 0.49
RARG P13631 10/20 0.48
RXRG P48443 7/20 0.48
RXRB P28702 6/20 0.48
RARB P10826 9/20 0.47
RARA P10276 8/20 0.44
CYP26A1 O43174 2/20 0.44
MEN1 O00255 1/20 0.44
ABCB11 O95342 1/20 0.44
ESR1 P03372 1/20 0.44
PGR P06401 1/20 0.44
HTR1A P08908 1/20 0.44
ADRA2A P08913 1/20 0.44
ADORA3 P0DMS8 1/20 0.44
CHRM1 P11229 1/20 0.44
DRD1 P21728 1/20 0.44
TBXA2R P21731 1/20 0.44
SLC6A2 P23975 1/20 0.44
ADRA1A P35348 1/20 0.44
OPRM1 P35372 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6477226 1.00 RXRA (0.49) RXRARARGRXRGRXRBRARB
SCHEMBL6032308 0.83 RXRA (0.52) RXRARARGRXRGRXRBRARB
SCHEMBL6818414 0.81 RXRA (0.50) RXRARARGRXRGRXRBRARB
SCHEMBL6876518 0.81 RXRA (0.50) RXRARARGRXRGRXRBRARB
SCHEMBL6818417 0.81 RXRA (0.50) RXRARARGRXRGRXRBRARB
SCHEMBL7022686 0.81 RARG (0.49) RXRARARGRXRGRXRBRARB
SCHEMBL6876810 0.80 RXRA (0.53) RXRARARGRXRGRXRBRARB
SCHEMBL6877496 0.80 RARG (0.48) RXRARARGRXRGRXRBRARB
SCHEMBL6874738 0.80 RXRA (0.67) RXRARARGRXRGRXRBRARB
SCHEMBL6032311 0.80 RXRA (0.67) RXRARARGRXRGRXRBRARB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US claimed
EP-0947496-B1 Bicyclic aromatic compounds and their use in human and veterinary medicine as well as in cosmetology GALDERMA RES & DEV (FR) 2002-10-09 EP claimed
US-6924388-B2 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2005-08-02 US disclosed
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) 2004-05-13 US disclosed
US-6632963-B1 Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) 2003-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092594-A1 Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof AHR, TYR, MC1R RXRA 174/4885RARG 302/4885RXRG 209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.